{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:10:52Z","timestamp":1761844252179},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/coc.0b013e3182868c66","type":"journal-article","created":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T13:18:46Z","timestamp":1367587126000},"page":"1-4","source":"Crossref","is-referenced-by-count":16,"title":["Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer"],"prefix":"10.1097","volume":"38","author":[{"given":"Howard","family":"Safran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin P.","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kaubisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalyan","family":"Mantripragada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Dubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Faricy-Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Miner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Victor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Plette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Espat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Bakalarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patti","family":"Wingate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Berz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Luppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Aparo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":". Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-1-20210128","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","article-title":". Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer.","volume":"23","author":"Philip","year":"2005","journal-title":"J Clin Oncol"},{"key":"R3-1-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":". Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and akt phosphorylation in vitro.","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"R4-1-20210128","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":". Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.","volume":"87","author":"Dredge","year":"2002","journal-title":"Br J Cancer"},{"key":"R5-1-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":". Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo.","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"R6-1-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568008033340207","article-title":"Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.","volume":"3","author":"Marriott","year":"2003","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"R7-1-20210128","first-page":"2975","article-title":". In vivo evaluation of immunomodulating effects of lenalidomide (L) on tumor cell microenvironment as a possible underlying mechanism of the antitumor effects observed in patients with chronic lymphocytic leukemia (CLL).","volume":"106","author":"Chanan-Khan","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"R8-1-20210128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","article-title":". Lenalidomide inhibits proliferation of namalwa CSN. 70 cells and interferes with gab1 phosphorylation and adaptor protein complex assembly.","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leuk Res"},{"key":"R9-1-20210128","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood.V108.11.2102.2102","article-title":". Pro-apoptotic effect of lenalidomide in patients with chronic lymphocytic leukemia is possibly mediated through interruption of the phosphatidylinositol pathway.","volume":"108","author":"Chanan-Khan","year":"2006","journal-title":"Blood"},{"key":"R10-1-20210128","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":". Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"R11-1-20210128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":". Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"R12-1-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":". Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"R13-1-20210128","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","article-title":". Evidence of a role for activation of Wntbeta-catenin signaling in the resistance of plasma cells to lenalidomide.","volume":"286","author":"Bjorklund","year":"2011","journal-title":"J Biol Chem"},{"key":"R14-1-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13277-012-0331-5","article-title":". Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.","volume":"33","author":"Kaur","year":"2012","journal-title":"Tumor Bio"},{"key":"R15-1-20210128","doi-asserted-by":"crossref","first-page":"e30601","DOI":"10.1371\/journal.pone.0030601","article-title":". Inhibition of Wntbeta-catenin signaling by a soluble collagen-derived frizzled domain interacting with Wnt3a and the receptors frizzled 1 and 8.","volume":"7","author":"Hendaoui","year":"2012","journal-title":"PLos One"},{"key":"R16-1-20210128","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1172\/JCI43937","article-title":". Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice.","volume":"122","author":"Anson","year":"2012","journal-title":"J Clin Invest"},{"key":"R17-1-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13277-012-0331-5","article-title":". Epigeneic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.","volume":"33","author":"Kaur","year":"2012","journal-title":"Tumour Biol"},{"key":"R18-1-20210128","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":". Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.","volume":"305","author":"Schafer","year":"2003","journal-title":"J Pharm Exp Therapeutics"},{"key":"R19-1-20210128","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":". Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"R20-1-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1743-7563.2009.01202.x","article-title":". Targeted agents for the systemic treatment of advanced hepatocellular carcinoma.","volume":"5","author":"Azad","year":"2009","journal-title":"Asia Pac J Clin Oncol"},{"key":"R21-1-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cncr.20821","article-title":". Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.","volume":"103","author":"Patt","year":"2005","journal-title":"Cancer"},{"key":"R22-1-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.20732","article-title":". Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.","volume":"103","author":"Lin","year":"2005","journal-title":"Cancer"},{"key":"R23-1-20210128","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000074477","article-title":". Low-dose thalidomide treatment for advanced hepatocellular carcinoma.","volume":"65","author":"Hsu","year":"2003","journal-title":"Oncology"},{"key":"R24-1-20210128","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents.","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R25-1-20210128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14712598.1.4.675","article-title":". Immunotherapeutic and antitumour potential of thalidomide analogues.","volume":"1","author":"Marriott","year":"2001","journal-title":"Expert Opin Biol Ther"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e3182868c66","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T13:19:36Z","timestamp":1688217576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201502000-00001"}},"subtitle":["A Brown University Oncology Group Phase II Study"],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3182868c66","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}